Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
Qaseem A, Obley AJ, Yost J, Abraham GM, Andrews RA, Jokela JA, Miller MC, Humphrey LL, Haeme R, Krain A, Poonacha T, Saini SD, Wilt TJ, Carroll K, Etxeandia-Ikobaltzeta I, Harrod CS, Shamliyan T, Vigna C. Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3). Ann Intern Med. 2026 Apr; 179(4):559-563.
-
Sun W, Weng W, Shi J, Ma B, D DeMarco K, Gui F, Jin R, Ruscetti M, Jia L, Hu W, Shi Y, Meng X. SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations. Bioconjug Chem. 2025 Oct 15; 36(10):2158-2171.
-
Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, Francis F, Buguzi CC, Moshi R, Garimo I, Lazaro S, Lusasi A, Aaron S, Chacky F, Mohamed A, Njau RJA, Kitau J, Rasmussen C, Bailey JA, Juliano JJ, Warsame M. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024 11; 24(11):1225-1233.
-
Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, Bakari C, Madebe RA, Seth MD, Mandara CI, Popkin-Hall ZR, Moshi R, Mbwambo RB, Niar? K, MacInnis B, Francis F, Mbwambo D, Garimo I, Chacky F, Aaron S, Lusasi A, Molteni F, Njau RJA, Nhiga SL, Mohamed A, Bailey JA, Ishengoma DS. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13?regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. 2024 10; 5(10):100920.
-
Mitchell CL, Janko MM, Verity R, Kashamuka MM, Bailey JA, Tshefu AK, Parr JB, Juliano JJ. Close Proximity to Mining Is Associated with Increased Prevalence of the Drug Resistance-Associated Mutation dhps540E in Eastern Democratic Republic of the Congo. Am J Trop Med Hyg. 2024 Aug 07; 111(2):361-364.
-
Som? AF, Conrad MD, Kabr? Z, Fofana A, Yerbanga RS, Bazi? T, Neya C, Som? M, Kagambega TJ, Legac J, Garg S, Bailey JA, Ou?draogo J-B, Rosenthal PJ, Cooper RA. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrob Agents Chemother. 2024 04 03; 68(4):e0153423.
-
Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, Sax PE. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023 11 11; 77(9):1257-1264.
-
Pillai RLI, Dziel C, Vogel S, Szczerba F, Chang WW, Camelo IY, Paez A. Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report. J Med Case Rep. 2023 Feb 24; 17(1):64.
-
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022; 17:3061-3073.
-
Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, Siler TM, Singh D, Wise RA, van Zyl-Smit RN, Berkman N. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.